Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. influenza west nile virus vaccine
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Influenza West Nile Virus Vaccine Articles & Analysis

27 articles found

Research Triangle Park, NC Large Influenza Vaccine Manufacturer - Case Study

Research Triangle Park, NC Large Influenza Vaccine Manufacturer - Case Study

We built a more than 700,000-cubic-foot vaccine storage solution for a global manufacturer, during COVID-19 lockdown, on time and on budget. ...

ByEnvironmental Specialties, LLC an EMCOR Group, Inc.


Innovation in the medical field

Innovation in the medical field

For centuries outbreaks of numerous diseases called pandemics would plague human populations in large regions or even world-wide. Throughout history there have been a number of widespread pandemics the most devastating being the Black Death pandemic that killed over 75 million people in the 1350’s and the latest being influenza outbreaks, also known as the Spanish flu, in 1918 and ...

ByMass Flow Online B.V.


Research And Development of Infectious Disease Vaccines

Research And Development of Infectious Disease Vaccines

As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development. ...

ByBiopharma PEG Scientific Inc


Breaking Barriers: Harnessing the Potential of Adjuvants in Vaccine Development

Breaking Barriers: Harnessing the Potential of Adjuvants in Vaccine Development

Infectious diseases seriously threaten human health, and various infectious diseases may cause millions of severe cases and even death every year. Vaccination has been one of the most effective public health interventions in history, preventing millions of deaths worldwide. However, the success of vaccines relies not only on the antigens they carry but also on additional components known as ...

ByAlfa Chemistry


Employee Spotlight: Vincent “D” Ming

Employee Spotlight: Vincent “D” Ming

Meet D, one of CSL Seqirus’ Senior Regional Account Managers by day and international lacrosse coach by night. His network of health care system accounts across Northern Texas, Oklahoma and New Mexico know him as D, their Senior Regional Account Manager, but he also goes by Coach D. Why? Because outside of supporting his region’s vaccination needs at CSL Seqirus, leading ...

ByCSL Seqirus UK Limited


What’s Top of Mind for Flu Researchers?

What’s Top of Mind for Flu Researchers?

Infectious diseases like influenza can be threats to public health and our economy. At the OPTIONS XI for the Control of Influenza conference, leading influenza vaccines provider CSL Seqirus, joined academic, government, research and industry stakeholders to discuss and learn more about influenza and its impact. Below, CSL Seqirus shared additional insights into topics of interest to the ...

ByCSL Seqirus UK Limited


Education’s Role in Fighting Infectious Diseases

Education’s Role in Fighting Infectious Diseases

Misinformation can have a profound impact on public health, experts say that education might be the key to combating it. According to the World Health Organization (WHO), immunization saves millions of lives each year. But given that many are still hesitant to get vaccinated for COVID-19, it is apparent that we are amidst an ‘infodemic’. “We’re not just battling ...

ByCSL Seqirus UK Limited


FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years

FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years

MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal ...

ByFluGen, Inc.


Flu Fighting Tips for Back to School

Flu Fighting Tips for Back to School

School is back in session, here’s what you need to know to help keep your family protected from flu. Influenza can be a real burden. It can spread rapidly between children and their families to have a significant impact on quality of life and disruption of usual activities: resulting in missed school days and for caregivers, missed work and illness themselves. So, here are a few ...

ByCSL Seqirus UK Limited


Flu is Making a Resurgence

Flu is Making a Resurgence

In 2022, flu cases in Australia have spiked earlier and with more cases this season than the previous five for the same time period. Experts discuss global implications of the surge. “Influenza is definitely back in the Southern Hemisphere,” said Professor Ian Barr, Deputy Director of The World Health Organization Collaborating Centre for Reference and Research on Influenza, ...

ByCSL Seqirus UK Limited


Nature Biotechnology: Generation of a live attenuated influenza A vaccine by proteolysis targeting

Nature Biotechnology: Generation of a live attenuated influenza A vaccine by proteolysis targeting

Longlong Si's research group from the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, published a research titled "Generation of a live attenuated influenza A vaccine by proteolysis targeting" in Nature Biotechnology. Using influenza virus as a model virus, the team established the technology of protein degradation targeting virus as an ...

ByProfacgen


The Art and Science of Shipping Flu Vaccines

The Art and Science of Shipping Flu Vaccines

CSL Seqirus delivered a record 135 million doses of flu vaccines globally last year, here’s how we make such a feat happen. Influenza vaccine manufacturing is an intricate and complex process that culminates in the summer months, when U.S. flu vaccine manufacturers receive regulatory approval from the FDA for the season’s vaccines. The manufacturers then prepare to distribute ...

ByCSL Seqirus UK Limited


Walk with Tab for Heart Health

Walk with Tab for Heart Health

Tab Lassiter – an employee of global vaccines leader CSL Seqirus – is about to receive a second transplant in an ongoing battle with a heart condition. He shares his story to explain why it’s critical to spread the word about heart health. Tab Lassiter once spent eight months resting anxiously in a hospital bed with cardiomyopathy, a condition that can lead to heart ...

ByCSL Seqirus UK Limited


Influenza Vaccination: Our Best Tool for Safeguarding Communities from Influenza

Influenza Vaccination: Our Best Tool for Safeguarding Communities from Influenza

Why we can’t overlook influenza in the midst of the ongoing COVID-19 pandemic. In many parts of the world, public health authorities are lifting social distancing, mask wearing and other COVID-19 mitigation measures in response to subsiding or stabilizing infection rates. But as daily life slowly returns to normal – and in the absence of an effective call to action on getting ...

ByCSL Seqirus UK Limited


The Network that Makes Seasonal Flu Vaccines Possible

The Network that Makes Seasonal Flu Vaccines Possible

Influenza is constantly mutating. 70 years ago, the World Health Organization set up a surveillance network to protect people from its threat. Making influenza vaccines that can help protect against viruses that threaten human health isn’t a simple process. It requires the cooperation between influenza vaccine manufacturers like Seqirus, and the World Health Organization’s ...

ByCSL Seqirus UK Limited


FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults

FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults

Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 – MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine ...

ByFluGen, Inc.


How pregnant women can protect themselves from COVID-19, flu and other viruses

How pregnant women can protect themselves from COVID-19, flu and other viruses

COVID-19 and viruses are a concern for all of us. Yet, anticipating a virus’s impact on an unborn child has heightened during the coronavirus pandemic for pregnant women or those expecting. However, there are tips you can take to protect yourself from viruses. ...

ByRespiray OU


Safeguarding Vaccines During This Flu Season

Safeguarding Vaccines During This Flu Season

As the COVID-19 pandemic continues across the world, it’s more important than ever to get a flu vaccine, as some predict natural immunity to be decreased following last year’s lockdowns.[i] To make sure influenza vaccinations are effective, they must be stored at the proper temperature. At the end of the cold chain, safe vaccine storage can only be assured through quality ...

ByB Medical Systems


Tackling the Global Vaccine Distribution Challenge

Tackling the Global Vaccine Distribution Challenge

A breakthrough in nanotechnology accelerates vaccine production While COVID-19 hotspots have continued to emerge driven by the Delta variants, the data still shows that vaccinations are effective at preventing hospitalizations and deaths. While over 4 billion vaccine doses have been administered worldwide, only 27% of the world’s population and only 1.1% of people in low-income countries ...

ByChemical Abstracts Service (CAS)


FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus

FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus

Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge ...

ByFluGen, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT